1. To advise on priorities for health technology assessment (HTA1 ), including
and having regard to:
2. To advise on new technologies where, because of their potential risk, cost, ethical implications or other relevant factors, there is a particular need to control diffusion until more information is available.
3. To advise on priorities for research into methodologies of relevance to HTA, and in particular:
4. To advise on training needs in respect of the conduct of high quality HTA.
1 HTA is used here to refer to the assessment of the effectiveness, costs and broader impact of all procedures used by the health professionals to promote health, to prevent and treat disease, and to improve rehabilitation and long term care.
To ask the Secretary of State for Health what is the budget of the NHS central research and development committee standing group on health technology.
The work of the standing group is challenging, and widespread consultation with the national health service, the professions, the research community and industry are essential. It is not possible to include expertise in all areas in one group and the standing group will be underpinned by six advisory panels covering the acute sector; pharmaceuticals; population screening; primary and community care; diagnostics, imaging and monitoring; and methodologies. Funding of this scientific support will be around £150,000 in 1993–94.
The priorities for research identified by the standing group will be brought to the attention of all relevant research funding bodies. Allocations of central and NHS resources to health technology assessment (HTA) will reflect the central research and development committee's views of the importance of this task in relation to other priorities, but it is anticipated that around half of NHS direct support for research will, in time, be allocated to HTA.